PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
The Paper and Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	09/770,901	
			Filing Date	January 26, 2001	
			First Named Inventor	Faour, J.	
			Group Art Unit	1617	
(use as many sheets as necessary)			Examiner Name	Shaojia A. Jiang	
Sheet	1 of	1	Attorney Docket Number	PHUS-28	

OTHER - NON PATENT LITERATURE DOCUMENTS							
Exam@ite InitialsNo.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ltem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
97	FUTAKI et al. in Abstract of Gen. Pharmacol. (1993), 24(1), 105-110						
	GANS et al. in Abstract of J. Pharmacol. Exp. Ther. (1990), 254(1), 180-187						
	TANAKA et al. in Abstract of Arnzneimittelforschung (1992), 42(7), 945-50						
	DIALOG™ database print-out						
	VERVURG et al. in Am. J. Therapeut. (2001), 8, 49-64						
	ROSENSTOCK et al. in Abstract of Biochim. Biophys. Acta (1999), 1440(1), 127-137						
	SAWADA et al. in Abstract of Immunopharmacology (2000), 49(3), 285-294						
560)	KULKARNI et al. in Methods and Findings in Experimental and Clinical Pharmacology (2000), 22(5), 291-298						
one Two or							
<u></u>							

Examiner Signature	Say	Date Considered	6	/21/8	4
				ί	/